Robert G. Partridge
Mr. Partridge brings marketing and communications experience spanning more than 20 years in the pharmaceutical industry to the CLS team. It marks the third major pharmaceutical effort headed up by Robert J. Bitterman, Sr., of which he’s been a part. He earned separate degrees in Business Administration/Marketing and International Politics, and has an extensive track record of successful messaging and positioning of brands and promotional campaigns both in and outside of U.S. markets. He has been a key member of launch and pre-launch teams for Sanofi-Aventis companies in the fields of oncology, hematology, and neurology prior to moving into dermatology in 1996. He led the launch of the first monoclonal antibody purified factor VIII replacement product, and worked on the pre-launch of Rhone-Poulenc Rorer’s lead chemotherapy product in the U.S., Taxotere. He also was part of the launch team for the first and only product approved by the FDA to treat amyotrophic lateral sclerosis, also known as Lou Gehrig’s Disease. His work also included a joint project with Dr. Jonas Salk’s ‘Immune Response Corporation’ which at the time was attempting to develop a successful vaccine for HIV. Within the dermatology specialty Mr. Partridge has experience with both medical and cosmetic product launches from a marketing and public relations perspective. He is the past Chairman for the Board of Directors of the Greater West Chester (PA) Chamber of Commerce. He also sits on two other non-profit Boards in the Southeastern Pennsylvania region, for the Franklin Mint Federal Credit Union with assets over $1 billion, and the West Chester Area Education Foundation.